Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma-Reference-Cited by-同舟云学术

Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

Published:2018-02 Issue:2 Volume:48 Page:210-220
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Intern Med J

Author:

Quach Hang¹²,Benson Simon³,Haysom Helen³⁴,Wilkes Anne-Marie⁵,Zacher Nicole³⁶,Cole-Sinclair Merrole²⁵,Miles Prince Henry¹⁷,Mollee Peter⁸,Spencer Andrew⁹¹⁰,Joy Ho Phoebe¹¹,Harrison Simon J.¹¹²,Lee Cindy¹³,Augustson Bradley¹⁴,Daly James³¹⁵

Affiliation:

1. Department of Medicine; The University of Melbourne; Melbourne Victoria Australia

2. Department of Haematology; St Vincent’s Hospital; Melbourne Victoria Australia

3. Australian and New Zealand Society of Blood Transfusion; Sydney New South Wales Australia

4. Department of Epidemiology and Preventive Medicine; Monash University; Melbourne Victoria Australia

5. Blood Transfusion Laboratory; St Vincent’s Hospital; Melbourne Victoria Australia

6. Clinical Diagnostic Department; Capital Pathology; Canberra Australian Capital Territory Australia

7. Department of Haematology; Epworth Health; Melbourne Victoria Australia

8. Department of Haematology; Princess Alexandra Hospital; Brisbane Queensland Australia

9. Australian Centre for Blood Diseases; Monash University; Melbourne Victoria Australia

10. Department of Haematology; Alfred Hospital; Melbourne Victoria Australia

11. Department of Haematology; Royal Prince Alfred Hospital; Sydney New South Wales Australia

12. Department of Haematology; Peter MacCallum Cancer Centre; Melbourne Victoria Australia

13. Department of Haematology; Royal Adelaide Hospital; Adelaide South Austalia Australia

14. Department of Haematology; Sir Charles Gairdner Hospital; Perth Western Australia Australia

15. QML Pathology; Brisbane Queensland Australia

Funder

Janssen-Cilag

Publisher

Wiley

Subject

Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imj.13707/fullpdf

Reference28 articles.

1. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma;Usmani;Blood,2016

2. Human CD38, a cell-surface protein with multiple functions;Mehta;FASEB J,1996

3. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma;Krejcik;Blood,2016

4. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors;Weers;J Immunol,2011

5. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking;Overdijk;J Immunol,2016

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interference of Monoclonal Antibody Therapy in Transfusion: An Update;Hemato;2024-07-02

2. Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials;Medicine;2023-09-22

3. Daratumumab: A drug with transfusion dilemma;Global Journal of Transfusion Medicine;2023

4. A Rare Case of Acute Hemolytic Anemia in a Patient with Newly Diagnosed Multiple Myeloma: Maintaining a Fine Balance between Occam's Razor and Hickam's Dictum;Indian Journal of Medical and Paediatric Oncology;2022-11-28

5. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment;Leukemia Research;2022-11